⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27261630 | 0.79 | — | — | |
| SCHEMBL5034219 | 0.77 | — | — | |
| Lithium Ion SCHEMBL25198385 | 0.76 | FFAR2 (0.36) | — | |
| SCHEMBL5875616 | 0.74 | — | — | |
| SCHEMBL3001292 | 0.74 | F2 (0.41) | — | |
| SCHEMBL24641060 | 0.74 | RAB9A (0.32) | — | |
| SCHEMBL279790 | 0.73 | — | — | |
| SCHEMBL1386669 | 0.73 | — | — | |
| SCHEMBL2893912 | 0.73 | — | — | |
| SCHEMBL2140479 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402875-A1 | S1P3 Antagonists | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2022-12-22 | — | — | US | claimed |
| CN-113358792-A | HPLC content analysis method of medicinal substance | 北京亚宝生物药业有限公司 | 2021-09-07 | — | — | CN | claimed |
| CN-113267584-A | HPLC related substance analysis method for medicinal substance | 北京亚宝生物药业有限公司 | 2021-08-17 | — | — | CN | claimed |
| EP-3689864-A1 | S1P3 ANTAGONISTS | Teva Pharmaceutical Industries Limited (IL) | 2020-08-05 | — | — | EP | claimed |
| US-20200157052-A1 | S1P3 Antagonists | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2020-05-21 | — | — | US | claimed |
| EP-3086845-B1 | S1P3 ANTAGONISTS | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2019-11-20 | — | — | EP | claimed |
| US-20180201582-A1 | S1P3 ANTAGONISTS | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2018-07-19 | — | — | US | claimed |
| EP-3086845-A1 | S1P3 ANTAGONISTS | Teva Pharmaceutical Industries Limited (IL) | 2016-11-02 | — | — | EP | claimed |
| US-20160297762-A1 | S1P3 ANTAGONISTS | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2016-10-13 | — | — | US | claimed |
| WO-2015082357-A1 | S1P3 ANTAGONISTS | SIENA BIOTECH S.P.A. (IT) | 2015-06-11 | — | — | WO | claimed |
| WO-2008104994-A2 | 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2008-09-04 | — | — | WO | claimed |
| JP-2006504796-A | — | — | 2006-02-09 | — | — | JP | claimed |
| EP-1551815-A1 | THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | claimed |
| US-6881844-B2 | Indole-3-carboxamides as glucokinase activators | HOFFMAN-LA ROCHE INC. (US) | 2005-04-19 | — | — | US | claimed |
| US-20040152747-A1 | Thiazole compounds for treatment of neurodegenerative disorders | PFIZER INC | 2004-08-05 | — | — | US | claimed |
| WO-2004033439-A1 | THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-04-22 | — | — | WO | claimed |
| US-20040067939-A1 | Indole-3-carboxamides as glucokinase activators | CORBETT WENDY LEA (US) | 2004-04-08 | — | — | US | claimed |
| JP-2003508353-A | — | — | 2003-03-04 | — | — | JP | claimed |
| EP-1208097-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | Aventis Pharmaceuticals Inc. (US) | 2002-05-29 | — | — | EP | claimed |
| WO-2001007436-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-02-01 | — | — | WO | claimed |